HR and breast carcinoma: A current clinical study (NCT05766410) is comparing the immunomodulatory effects of palbociclib, ribociclib and abemaciclib each combined with letrozole in the neoadjuvant setting for HR+/HER2− early-stage breast cancer; the trial is actively recruiting and its results are eagerly awaited.